The investigators induced polymicrobial sepsis via cecal ligation and puncture (CLP) in mice and tested whether peripheral stimulation could recruit brainstem circuits to influence systemic immunity. In Experiment 1, fifty C57BL/6 mice were randomized to five groups (sham operation, model, antibiotic, electroacupuncture, and EA + antibiotic), with 10 mice per arm. The study team performed EA at bilateral Zusanli (ST36) for 15 minutes using 10 Hz and 0.5 mA once daily for three days. Antibiotic therapy consisted of intraperitoneal imipenem-cilastatin sodium, 30 mg/kg given every 12 hours for three days. The primary observational window reported in the abstract was the first 3 days after CLP.
The CLP model produced the expected acute phenotype: the model group showed sharply reduced 3-day survival and significant body weight loss compared with sham (P <0.0001). Serum inflammatory mediators—IL-6 and TNF-α—were elevated in the model group, and HE staining revealed marked inflammatory cell infiltration in cecal tissue (P <0.0001 for these comparisons). When EA was combined with antibiotics, the cohort showed improved 3-day survival (P <0.05), attenuated body weight loss (P <0.0001), lower serum IL-6 and TNF-α levels (P <0.0001), and reduced inflammatory infiltration of the cecum (P <0.0001). The study team also observed an increase in c-Fos–positive cell density within the dorsal motor nucleus of vagus (DMV) in the EA + antibiotic group versus the untreated model (P <0.0001), suggesting activation of DMV neurons after the combined intervention.
To test causality for DMV neuronal involvement, the authors ran a second experiment using Chat-Cre mice with targeted viral manipulation of DMV neurons. Fifty Chat-Cre mice were allocated to five groups: sham + empty virus, model + empty virus, EA + antibiotic + empty virus, EA + antibiotic + inhibitory virus, and antibiotic + activating virus (10 mice per group). Viruses were injected into the DMV three weeks prior to CLP. Following model induction, mice received daily clozapine N-oxide (CNO, 3 mg/kg) intraperitoneally as part of the chemogenetic protocol, combined with the same EA and antibiotic regimens used in Experiment 1. Outcome measures reported in the abstract included serum IL-6 and TNF-α, cecal histopathology by HE, and DMV modulation by viral tools. The abstract indicates the investigators used these viral tools to probe the role of DMV neurons in mediating the observed anti-inflammatory and survival effects, but the abstract does not provide the full numeric outcomes for each viral group.
The study team measured systemic catecholamines and metabolites using ultra-high performance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS). Reported analytes included dopamine (DA), epinephrine (E), norepinephrine (NE), and their metabolites 3-methoxytyramine (3-MT), normetanephrine (NMN), and metanephrine (MN). Immunofluorescence was used to quantify FOXP3+/CD4+ cells in cecal tissue as a readout of local regulatory T-cell presence. These assays were part of Experiment 2, intended to link DMV modulation, catecholamine release, and local immune regulation in the gut during sepsis. The abstract confirms these measures were taken but does not state the explicit concentration values or provide the complete comparative statistics in the accessible text.
Across the reported comparisons, the authors noted strong statistical signals for the primary acute endpoints: survival, weight loss, serum IL-6 and TNF-α, and cecal inflammatory infiltration. Many group differences versus the CLP model reached highly significant P thresholds (multiple results cited at P <0.0001). The EA + antibiotic combination specifically yielded an upward shift in DMV c-Fos expression concurrent with improvements in systemic inflammatory markers and short-term survival. The abstract frames these observations as evidence that EA targeting peripheral acupoints can engage the vagus-adrenal axis through DMV neuronal activation and modify the early course of experimental sepsis.
The PubMed abstract does not include several details that clinicians and translational researchers will want to see. The accessible text does not report exact numeric catecholamine or metabolite concentrations, nor does it present the full set of group-by-group statistics for Experiment 2 viral manipulations. Long-term survival beyond the 3-day window was not described in the abstract. The source did not report any safety or adverse-effect data related to EA or the chemogenetic intervention in the abstract. Detailed methods for the viral constructs, viral titers, precise stereotaxic coordinates, and full immunofluorescence quantification workflows are not included in the PubMed abstract. Readers interested in those specifics will need to consult the full text.
Limitations explicitly documented in the abstract are limited to reported observation windows and measured endpoints; the abstract itself does not provide an extended discussion of translational constraints. The source did not report clinical trials or human data; findings are preclinical and confined to murine CLP models with acute (3-day) outcome measures.